SpringerLink
Log in

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas

  • COMMENTARY
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Srinivas NR. Pharmacodynamics of insulin preparations administered in different subcutaneous injection sites: are there differences between healthy subjects versus diabetic patients? Clin Drug Investig. 2017. doi:10.1007/s40261-017-0538-8

  2. Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Morschel L, Forst T. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016;18(10):962–72.

    Article  CAS  PubMed  Google Scholar 

  3. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51(10):1790–5.

    Article  CAS  PubMed  Google Scholar 

  4. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501–6.

    Article  CAS  PubMed  Google Scholar 

  5. Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H. Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions. Clin Drug Investig. 2017;37(5):503–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Nosek L, Coester HV, Roepstorff C, Thomsen HF, Kristensen NR, Haahr H, et al. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. Clin Drug Investig. 2014;34(9):673–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Süsstrunk H, Morell B, Ziegler WH, Froesch ER. Insulin absorption from the abdomen and the thigh in healthy subjects during rest and exercise: blood glucose, plasma insulin, growth hormone, adrenaline and noradrenaline levels. Diabetologia. 1982;22:171–4.

    Article  PubMed  Google Scholar 

  8. ter Braak E, Woodworth JR, Bianchi R, Cerimelle B, Erkelens DW, Thijssen JH, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996;19:1437–40.

    Article  PubMed  Google Scholar 

  9. Koivisto VA, et al. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92:59–61.

    Article  CAS  PubMed  Google Scholar 

  10. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5(2):77–91.

    Article  CAS  PubMed  Google Scholar 

  11. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16:1592–7.

    Article  CAS  PubMed  Google Scholar 

  12. Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, Johnston DG. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol (Oxf). 1991;35(5):409–12.

    Article  CAS  Google Scholar 

  13. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005;27(2):210–5.

    Article  CAS  PubMed  Google Scholar 

  14. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15:1484–93.

    Article  CAS  PubMed  Google Scholar 

  15. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (Onset 1). Diabetes Care. 2017.

  17. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56(5):551–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;30(6):CD012161.

    Google Scholar 

  19. Henriksen JE, Djurhuus MS, Vaag A, Thye Ronn P, Knudsen D, Hother Nielsen O, et al. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia. 1993;36:752–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Profil, Neuss, Germany

    Tim Heise, Ulrike Hövelmann, Leszek Nosek & Bettina Sassenfeld

  2. Novo Nordisk, Aalborg Ø, Denmark

    Karen Margrete Due Thomsen

  3. Novo Nordisk, Søborg, Denmark

    Hanne Haahr

Authors
  1. Tim Heise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrike Hövelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leszek Nosek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bettina Sassenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karen Margrete Due Thomsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hanne Haahr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tim Heise.

Additional information

This reply refers to the article available at doi:10.1007/s40261-017-0499-y.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heise, T., Hövelmann, U., Nosek, L. et al. Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas. Clin Drug Investig 37, 885–887 (2017). https://doi.org/10.1007/s40261-017-0539-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-017-0539-7

Search

Navigation